Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
1. A method to induce an immune response in a human patient against an antigen, comprising administering to said patient an effective amount of said antigen and carrier, wherein such antigen has been chemically modified with a compound of formula αGal-N(CH 3 )—O—R 1 —COOR 2 , wherein αGal is a trisaccharide of formula Galα1-3Galβ1-4Glc, or Galα1-3Galβ1-4GlcNAc, wherein R 1 is any linear or branched alkyl group of 1 to 30 carbon atoms, wherein one or more carbon atoms in said alkyl group can be substituted by O, S, or N and wherein one or more hydrogens can be substituted by hydroxyl, carbonyl, alkyl, sulphydryl or amino groups, and wherein R 2 is an amino or sulphydryl reacting group, and a carrier.